Manidón (Verapamil Hydrochloride)

Verapamil blocks L‑type calcium channels in cardiac and vascular smooth muscle. By reducing calcium entry into cells, it decreases myocardial contractility, slows atrioventricular nodal conduction, and causes arterial vasodilation, which together lower blood pressure and stabilize cardiac rhythm.

The appropriate dose of Manidón is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Dosage regimens are individualized and should follow the prescriber’s instructions and local clinical guidelines.

Safety data for verapamil in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any potential risk to the fetus or infant. Clinicians must evaluate the risk‑benefit profile for each patient.

To request Manidón, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Manidón (verapamil) belongs to the calcium‑channel blocker class, whereas many alternative anti‑arrhythmics, such as class III agents (e.g., amiodarone), act on potassium channels. Verapamil is particularly effective for rate control in atrial fibrillation and for treating supraventricular tachycardia, offering a different side‑effect profile and contraindications compared with sodium‑channel blockers.

Manidón should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Manidón is supplied as an injectable solution for intravenous administration. It is typically infused slowly under clinical supervision, with dosing and infusion rate determined by the treating physician based on the patient’s cardiac status and therapeutic goals.

Serious adverse events include marked bradycardia, severe hypotension, advanced atrioventricular block, and rare allergic reactions such as anaphylaxis. Patients should be monitored continuously during infusion, and any signs of these conditions require immediate medical intervention.

Manidón is contraindicated in patients with known hypersensitivity to verapamil or other calcium‑channel blockers, those with severe sinus bradycardia, second‑ or third‑degree AV block without a pacemaker, and patients with uncompensated heart failure. Clinicians must assess each individual’s medical history before prescribing.